TrialBreast cancer (Tokyo, Japan)2023

Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).

Manabu Futamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.